Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Theravance Biopharma (TBPH) over the last 12 years, with Q3 2025 value amounting to -$920.7 million.

  • Theravance Biopharma's Retained Earnings rose 308.89% to -$920.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$920.7 million, marking a year-over-year increase of 308.89%. This contributed to the annual value of -$965.5 million for FY2024, which is 620.59% down from last year.
  • As of Q3 2025, Theravance Biopharma's Retained Earnings stood at -$920.7 million, which was up 308.89% from -$924.3 million recorded in Q2 2025.
  • Theravance Biopharma's 5-year Retained Earnings high stood at -$843.5 million for Q3 2022, and its period low was -$1.8 billion during Q2 2022.
  • In the last 5 years, Theravance Biopharma's Retained Earnings had a median value of -$937.3 million in 2024 and averaged -$1.2 billion.
  • Its Retained Earnings has fluctuated over the past 5 years, first crashed by 2062.42% in 2021, then skyrocketed by 5052.78% in 2022.
  • Quarter analysis of 5 years shows Theravance Biopharma's Retained Earnings stood at -$1.7 billion in 2021, then skyrocketed by 50.53% to -$853.9 million in 2022, then fell by 6.46% to -$909.1 million in 2023, then fell by 6.21% to -$965.5 million in 2024, then rose by 4.65% to -$920.7 million in 2025.
  • Its last three reported values are -$920.7 million in Q3 2025, -$924.3 million for Q2 2025, and -$979.1 million during Q1 2025.